Related Experiment Videos
Actual and estimated replication costs for alcohol treatment modalities: case study from Project MATCH
R Cisler1, H D Holder, R Longabaugh
1Center for Addiction and Behavioral Health Research, University of Wisconsin-Milwaukee, 53201-0786, USA.
Journal of Studies on Alcohol
|August 26, 1998
Summary
Project MATCH alcohol treatments are costly in research settings. However, Motivational Enhancement Therapy (MET) is significantly less expensive to replicate in nonresearch clinical settings compared to Cognitive Behavioral Therapy (CBT) and Twelve-Step Facilitation (TSF).
Area of Science:
- Health economics
- Addiction treatment
- Clinical trial cost analysis
Background:
- Project MATCH evaluated three manual-guided, individually delivered alcohol treatments: Cognitive Behavioral Therapy (CBT), Motivational Enhancement Therapy (MET), and Twelve-Step Facilitation (TSF).
- A comprehensive cost-effectiveness analysis requires understanding the relative costs of these treatments in both research and real-world clinical settings.
Purpose of the Study:
- To examine the relative costs of CBT, MET, and TSF as delivered in a randomized trial.
- To estimate the costs of replicating these three alcohol treatments in nonresearch clinical settings.
Main Methods:
- Costs were assessed for 12-session CBT, 4-session MET, and 12-session TSF over 12 weeks at two Project MATCH sites.
- Research cost calculations included clinical, administrative, and training/supervision variables.
- Investigators estimated replication costs for direct clinical expenses, administrative overhead, and training/supervision.
Main Results:
- In the research setting, MET had higher cost per contact hour ($498) than CBT ($198) and TSF ($253), but lower cost per participant ($1,700) than CBT ($1,901) and TSF ($1,969).
- For clinical replication, per-patient costs ranged from $512 (MET) to $750 (TSF) to $788 (CBT).
- MET demonstrated significant cost savings in replication: $238 (32%) less than TSF and $276 (35%) less than CBT.
Conclusions:
- Project MATCH treatments are expensive to produce within a clinical trial setting.
- Replicating these treatments in nonresearch clinical settings substantially reduces costs.
- MET appears to be the most cost-effective treatment for replication in nonresearch settings.